352 related articles for article (PubMed ID: 29973365)
1. Preservatives in glaucoma medication.
Steven DW; Alaghband P; Lim KS
Br J Ophthalmol; 2018 Nov; 102(11):1497-1503. PubMed ID: 29973365
[TBL] [Abstract][Full Text] [Related]
2. Clinical audit examining the impact of benzalkonium chloride-free anti-glaucoma medications on patients with symptoms of ocular surface disease.
Goldberg I; Graham SL; Crowston JG; d'Mellow G;
Clin Exp Ophthalmol; 2015 Apr; 43(3):214-20. PubMed ID: 25196488
[TBL] [Abstract][Full Text] [Related]
3. Ocular benzalkonium chloride exposure: problems and solutions.
Goldstein MH; Silva FQ; Blender N; Tran T; Vantipalli S
Eye (Lond); 2022 Feb; 36(2):361-368. PubMed ID: 34262161
[TBL] [Abstract][Full Text] [Related]
4. Ocular Surface Disease in Glaucoma: Effect of Polypharmacy and Preservatives.
Ramli N; Supramaniam G; Samsudin A; Juana A; Zahari M; Choo MM
Optom Vis Sci; 2015 Sep; 92(9):e222-6. PubMed ID: 25730335
[TBL] [Abstract][Full Text] [Related]
5. Ocular Surface Disease in Glaucoma Patients Randomized to Benzalkonium Chloride-Containing Latanoprost and Preservative-Free Bimatoprost.
Wu JH; Wang TH; Huang JY; Su CC
J Ocul Pharmacol Ther; 2021 Dec; 37(10):556-564. PubMed ID: 34610257
[No Abstract] [Full Text] [Related]
6. Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma.
Baudouin C
Acta Ophthalmol; 2008 Nov; 86(7):716-26. PubMed ID: 18537937
[TBL] [Abstract][Full Text] [Related]
7. Ocular Surface Disease in Patients under Topical Treatment for Glaucoma.
Pérez-Bartolomé F; Martínez-de-la-Casa JM; Arriola-Villalobos P; Fernández-Pérez C; Polo V; García-Feijoó J
Eur J Ophthalmol; 2017 Nov; 27(6):694-704. PubMed ID: 28497458
[TBL] [Abstract][Full Text] [Related]
8. Glaucoma therapy and ocular surface disease: current literature and recommendations.
Anwar Z; Wellik SR; Galor A
Curr Opin Ophthalmol; 2013 Mar; 24(2):136-43. PubMed ID: 23542350
[TBL] [Abstract][Full Text] [Related]
9. Risk factors to develop ocular surface disease
in treated glaucoma or ocular hypertension patients.
Rossi GC; Pasinetti GM; Scudeller L; Raimondi M; Lanteri S; Bianchi PE
Eur J Ophthalmol; 2013; 23(3):296-302. PubMed ID: 23335308
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety evaluation of benzalkonium chloride preserved eye-drops compared with alternatively preserved and preservative-free eye-drops in the treatment of glaucoma: a systematic review and meta-analysis.
Hedengran A; Steensberg AT; Virgili G; Azuara-Blanco A; Kolko M
Br J Ophthalmol; 2020 Nov; 104(11):1512-1518. PubMed ID: 32051133
[TBL] [Abstract][Full Text] [Related]
11. How ocular surface disease impacts the glaucoma treatment outcome.
Kaštelan S; Tomić M; Metež Soldo K; Salopek-Rabatić J
Biomed Res Int; 2013; 2013():696328. PubMed ID: 24224176
[TBL] [Abstract][Full Text] [Related]
12. Effects of benzalkonium chloride-preserved, polyquad-preserved, and sofZia-preserved topical glaucoma medications on human ocular epithelial cells.
Ammar DA; Noecker RJ; Kahook MY
Adv Ther; 2010 Nov; 27(11):837-45. PubMed ID: 20931366
[TBL] [Abstract][Full Text] [Related]
13. The treatment of glaucoma using topical preservative-free agents: an evaluation of safety and tolerability.
Konstas AG; Labbé A; Katsanos A; Meier-Gibbons F; Irkec M; Boboridis KG; Holló G; García-Feijoo J; Dutton GN; Baudouin C
Expert Opin Drug Saf; 2021 Apr; 20(4):453-466. PubMed ID: 33478284
[No Abstract] [Full Text] [Related]
14. Prescription trends for preservative free glaucoma medication in a public health system.
Pérez-García P; Burgos-Blasco B; Morales-Fernández L; Fernández-Ruiz-Morón A; Gómez-Calleja V; Oribio-Quinto C; Collado-Vincueria I; Garcia-Feijoo J; Martinez-de-la-Casa JM
Eur J Ophthalmol; 2024 Jan; 34(1):193-203. PubMed ID: 37070183
[TBL] [Abstract][Full Text] [Related]
15. Effects of common ophthalmic preservatives on ocular health.
Noecker R
Adv Ther; 2001; 18(5):205-15. PubMed ID: 11783457
[TBL] [Abstract][Full Text] [Related]
16. Preservative exposure and surgical outcomes in glaucoma patients: The PESO study.
Boimer C; Birt CM
J Glaucoma; 2013 Dec; 22(9):730-5. PubMed ID: 23524856
[TBL] [Abstract][Full Text] [Related]
17. [Corneal sensitivity in patients treated medically for glaucoma or ocular hypertension].
Van Went C; Alalwani H; Brasnu E; Pham J; Hamard P; Baudouin C; Labbé A
J Fr Ophtalmol; 2011 Dec; 34(10):684-90. PubMed ID: 22093372
[TBL] [Abstract][Full Text] [Related]
18. [Effects of preservatives in anti-glaucoma agents on the ocular surface].
Potop V
Oftalmologia; 2009; 53(2):92-6. PubMed ID: 19697847
[TBL] [Abstract][Full Text] [Related]
19. Preservative use in topical glaucoma medications.
Tressler CS; Beatty R; Lemp MA
Ocul Surf; 2011 Jul; 9(3):140-58. PubMed ID: 21791189
[TBL] [Abstract][Full Text] [Related]
20. Relative efficacy and safety of preservative-free latanoprost (T2345) for the treatment of open-angle glaucoma and ocular hypertension: an adjusted Indirect comparison meta-analysis of randomized clinical trials.
Cucherat M; Stalmans I; Rouland JF
J Glaucoma; 2014 Jan; 23(1):e69-75. PubMed ID: 23881267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
